Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06455202

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Chronic Spontaneous Urticaria Chronic Disease Chronic Urticaria Disease Attributes Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Skin Diseases Skin Diseases, Vascular Skin and Connective Tissue Diseases Urticaria

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Novatrials, Charlestown, New South Wales, Australia

Loading trial locations.

About this study

This is a global, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study investigating the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who are symptomatic despite treatment with non-sedating second generation H1-antihistamines at 1-4 times the locally approved dose.

There is a screening period of up to 4 weeks, followed by a 24-week placebo-controlled treatment period, a 28-week active treatment period where all participants receive barzolvolimab followed by a 16-week treatment free period.

Approximately 915 adult participants (610 in the active arms and 305 in the placebo arm) will be randomly assigned to the treatment arms.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Males and females, >/= 18 years of age.
  • Chronic spontaneous urticaria (CSU) >/= 6 months prior to Screening (Visit 1).
  • CSU despite the use of a stable regimen of second generation non-sedating H1-antihistamine as defined by:
  • The presence of hives for >/= 6 weeks at any time prior to Visit 1 despite the use of non-sedating H1-antihistamines.
  • Must be on a stable regimen of second generation non-sedating H1-antihistamine for >/= 4 weeks prior to study treatment.
  • UAS7 of >/= 16 and ISS7 of >/= 8 during the 7 days prior to study treatment.
  • Normal blood counts and liver function tests.
  • Both males and females of child-bearing potential must agree to use highly effective contraceptives during the study and for 150 days after treatment.
  • Willing and able to complete a daily symptom electronic diary and comply with study visits.
  • Participants with and without prior biologic experience are eligible.

Key Exclusion Criteria:

  • Women who are pregnant or nursing.
  • Chronic urticaria whose predominant manifestation is due to CIndU.
  • Other diseases associated with urticaria.
  • Active pruritic skin condition in addition to CSU.
  • Medical condition that would cause additional risk or interfere with study procedures.
  • Known HIV, hepatitis B or hepatitis C infection.
  • Vaccination of a live vaccine within 30 days prior to Screening (Visit 1) (subjects must agree to avoid live vaccinations during the study). Inactivated vaccines are allowed such as seasonal influenza injection or authorized COVID-19 vaccine.
  • History of anaphylaxis
  • Prior treatment with barzolvolimab

There are additional criteria that your study doctor will review with you to confirm you are eligible for the study.

Treatment and study plan

barzolvolimab

Biological

Subcutaneous Administration

Matching Placebo

Biological

Matching placebo Subcutaneous Administration

Primary outcomes

  1. Mean change from baseline to Week 12 of UAS7 (Urticaria Activity Score)

    Time frame: From Day 1 (first dose) to Day 85 (Week 12)

    Evaluate efficacy of barzolvolimab on urticaria activity as measured by urticaria activity score (UAS).

    The UAS7 is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42, and a minimum possible score of 0.

Secondary outcomes

  1. Mean change from baseline to Week 12 of ISS7 (Itch Severity Score)

    Time frame: From Day 1 (first dose) to Day 85 (Week 12)

    The ISS7 and HSS7 combined together make up the UAS7 scoring system to evaluate urticaria signs and symptoms. The ISS7 is the itch severity score for 7 days, the scores range from 0 to 21.

  2. Mean change from baseline to Week 12 of HSS7 (Hives Severity Score)

    Time frame: From Day 1 (first dose) to Day 85 (Week 12)

    The ISS7 and HSS7 combined together make up the UAS7 scoring system to evaluate urticaria signs and symptoms. The HSS7 score is the wheal/hives severity score for 7 days, the scores range from 0 to 21.

  3. Percentage of patients with UAS7=0 at Week 12

    Time frame: From Day 1 (first dose) to Day 85 (Week 12)

    Proportion of participants who achieve complete absence of hives and itch (UAS7 = 0) at Week 12.

  4. Percentage of participants with UAS7 ≤ 6 at Week 12

    Time frame: From Day 1 (first dose) to Day 85 (Week 12)

    Proportion of participants who achieve control of their urticaria signs and symptoms (UAS7≤6) at Week 12.

  5. Percentage of participants with AAS7 > 0 at baseline with AAS7 = 0 at Week 12

    Time frame: From Day 1 (first dose) to Day 85 (Week 12)

    Proportion of participants with AAS7 > 0 at Day 1 who achieved complete control (AAS7 = 0) at Week 12

    Angioedema Activity Score over 7 days [AAS7] describes the effect of angioedema on five categories with 0 being none and 3 being most severe. The final score is calculated by adding together daily scores which can range from 0-15 for 7 days. The resulting maximum score is then 105.

  6. Mean change from baseline in UAS7 in participants refractory to omalizumab treatment at Week 12

    Time frame: From Day 1 (first dose) to Day 85 (Week 12)

    Evaluate efficacy of barzolvolimab on urticaria activity as measured by urticaria activity score (UAS) in participants who did not respond to or did not tolerate omalizumab.

    The UAS7 is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42, and a minimum possible score of 0.

  7. Proportion of participants with UAS7 = 0 in participants refractory to omalizumab treatment at Week 12

    Time frame: From Day 1 (first dose) to Day 85 (Week 12)

    Proportion of participants who achieve complete absence of hives and itch (UAS7 = 0) at Week 12 in participants who did not respond to or did not tolerate omalizumab.

  8. Incidence of Treatment-Emergent Adverse Events

    Time frame: From Day 1 (first dose) to Day 477 (Week 68)

    Occurrence of treatment emergent adverse events and serious adverse events during the study.

Sponsors and collaborators

Lead sponsor

Celldex Therapeutics

Industry

Registry information

Official study title

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU2)

Acronym: EMBARQ-CSU2

Important dates

Study start
2024
Primary completion
2026
Study completion
2027
First posted
Jun 12, 2024
Registry last updated
Mar 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.